GB1381872A
(en)
*
|
1971-06-22 |
1975-01-29 |
Fisons Ltd |
Pharmaceutical compositions for inhalation
|
BE787100A
(en)
*
|
1971-08-06 |
1973-02-02 |
Beecham Group Ltd |
COMPOSITION FOR THE TREATMENT OF ASTHMA
|
GB1410588A
(en)
*
|
1971-08-10 |
1975-10-22 |
Fisons Ltd |
Composition
|
DE2332663C2
(en)
*
|
1973-06-23 |
1986-07-31 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
Use of corticosteroid active ingredients for inhalation therapy
|
DE2535258C2
(en)
*
|
1974-08-10 |
1993-06-03 |
Fisons Plc, Ipswich, Suffolk |
Inhalable drug in pellet form
|
US4161516A
(en)
*
|
1975-07-25 |
1979-07-17 |
Fisons Limited |
Composition for treating airway disease
|
FI770215A
(en)
*
|
1976-01-30 |
1977-07-31 |
Fisons Ltd |
|
CY1333A
(en)
*
|
1980-04-30 |
1986-10-24 |
Fisons Ltd |
Pharmaceutical compositions containing cromoglycates
|
BE891013A
(en)
*
|
1980-11-05 |
1982-05-05 |
Fisons Ltd |
PHARMACEUTICAL COMPOSITIONS
|
JPS59163313A
(en)
*
|
1983-03-09 |
1984-09-14 |
Teijin Ltd |
Peptide hormone composition for nasal administration
|
JP2770970B2
(en)
*
|
1987-04-09 |
1998-07-02 |
フアイソンズ・ピーエルシー |
Pharmaceutical composition containing pentamidine
|
US5204113A
(en)
*
|
1987-04-09 |
1993-04-20 |
Fisons Plc |
Pharmaceutical compositions containing pentamidine
|
DE4140689B4
(en)
*
|
1991-12-10 |
2007-11-22 |
Boehringer Ingelheim Kg |
Inhalable powders and process for their preparation
|
EP0606486B1
(en)
*
|
1992-06-12 |
2001-08-29 |
Teijin Limited |
Pharmaceutical preparation for intra-airway administration
|
US6794357B1
(en)
|
1993-06-24 |
2004-09-21 |
Astrazeneca Ab |
Compositions for inhalation
|
US5830853A
(en)
|
1994-06-23 |
1998-11-03 |
Astra Aktiebolag |
Systemic administration of a therapeutic preparation
|
US6632456B1
(en)
|
1993-06-24 |
2003-10-14 |
Astrazeneca Ab |
Compositions for inhalation
|
SG48049A1
(en)
*
|
1993-10-01 |
1998-04-17 |
Astra Ab |
Process i
|
IS1736B
(en)
|
1993-10-01 |
1999-12-30 |
Astra Ab |
Methods and devices that promote increased particle aggregation
|
NL9301851A
(en)
*
|
1993-10-26 |
1995-05-16 |
Cordis Europ |
Cryo-ablation catheter.
|
GB9322014D0
(en)
|
1993-10-26 |
1993-12-15 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
GB9404945D0
(en)
|
1994-03-15 |
1994-04-27 |
Glaxo Group Ltd |
Pharmaceutical composition
|
US6102036A
(en)
*
|
1994-04-12 |
2000-08-15 |
Smoke-Stop |
Breath activated inhaler
|
US6165976A
(en)
|
1994-06-23 |
2000-12-26 |
Astra Aktiebolag |
Therapeutic preparation for inhalation
|
DE4425255A1
(en)
*
|
1994-07-16 |
1996-01-18 |
Asta Medica Ag |
Formulation for inhalation application
|
KR100389080B1
(en)
|
1994-12-22 |
2003-10-17 |
아스트라제네카 악티에볼라그 |
Therapeutic Preparation for Inhalation Containing Parathyroid Hormone, PTH
|
US6524557B1
(en)
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
GB9501841D0
(en)
|
1995-01-31 |
1995-03-22 |
Co Ordinated Drug Dev |
Improvements in and relating to carrier particles for use in dry powder inhalers
|
US6648848B1
(en)
*
|
1997-05-27 |
2003-11-18 |
Direct-Haler A/S |
Inhaler for powdered medicaments
|
PL200940B1
(en)
*
|
1998-08-18 |
2009-02-27 |
Univ California |
Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
ITMI991582A1
(en)
|
1999-07-16 |
2001-01-16 |
Chiesi Farma Spa |
DUST CONSTITUTED FROM PARTICLES HAVING THE PERFECTLY SMOOTH SURFACE FOR USE AS VEHICLES FOR THE PREPARATION OF INALA MIXTURES
|
GB9920839D0
(en)
|
1999-09-04 |
1999-11-10 |
Innovata Biomed Ltd |
Inhaler
|
EP1129705A1
(en)
*
|
2000-02-17 |
2001-09-05 |
Rijksuniversiteit te Groningen |
Powder formulation for inhalation
|
PE20011227A1
(en)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
|
GB0009469D0
(en)
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
AU757008B2
(en)
*
|
2000-10-12 |
2003-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel tiotropium-containing inhalation powder
|
UA75375C2
(en)
*
|
2000-10-12 |
2006-04-17 |
Boehringer Ingelheim Pharma |
Method for producing powdery preparations for inhaling
|
US20060194773A1
(en)
*
|
2001-07-13 |
2006-08-31 |
Paratek Pharmaceuticals, Inc. |
Tetracyline compounds having target therapeutic activities
|
DE10141377A1
(en)
*
|
2001-08-23 |
2003-03-13 |
Boehringer Ingelheim Pharma |
Scattering process for the production of powder formulations
|
US8337816B2
(en)
*
|
2001-09-17 |
2012-12-25 |
Glaxo Group Limited |
Dry powder medicament formulations
|
EP1458362A4
(en)
*
|
2001-11-19 |
2006-01-18 |
Becton Dickinson Co |
Pharmaceutical compositions in particulate form
|
GB0128148D0
(en)
|
2001-11-23 |
2002-01-16 |
Innovata Biomed Ltd |
Assembly
|
US6900317B2
(en)
*
|
2002-02-19 |
2005-05-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
|
US20040014679A1
(en)
*
|
2002-02-20 |
2004-01-22 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Inhalation powder containing the CGRP antagonist BIBN4096 and process for the preparation thereof
|
DE10207026A1
(en)
*
|
2002-02-20 |
2003-08-28 |
Boehringer Ingelheim Kg |
Stable inhalable powder of the calcitonin gene-related peptide antagonist, BIBN4096, useful for treating migraine, in the form of spherical nano-structured particles obtained by spray-drying
|
JP2006516531A
(en)
*
|
2002-08-21 |
2006-07-06 |
ノートン ヘルスケアー リミテッド |
Inhalation composition
|
DE10255387A1
(en)
*
|
2002-11-28 |
2004-06-09 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New tiotropium-containing powder formulation for inhalation
|
US7763280B2
(en)
*
|
2002-11-28 |
2010-07-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Tiotropium containing powder formulation for inhalation
|
DE10317461A1
(en)
|
2003-04-16 |
2004-10-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
|
DE10338407A1
(en)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New inhalable powders containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine
|
US20050042178A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
|
US20050042179A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Inhalative powder formulations containing the CGRP-antagonist 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine
|
DE10338402A1
(en)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried, amorphous BIBN 4096, process for its preparation and its use as inhalant
|
DE10338403A1
(en)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder formulation containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1 H) -oxoquinazolin-3-yl] -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyrindinyl) piperazine, process for its preparation and its use as inhalant
|
DE10338399A1
(en)
*
|
2003-08-18 |
2005-03-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Microparticles containing the CGRP antagonist 1- [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl] -L-lysyl] -4- (4-pyridinyl) -piperazine, process for their preparation and their use as inhalation powder
|
US20050043247A1
(en)
*
|
2003-08-18 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Spray-dried amorphous BIBN 4096, process for preparing and the use thereof as inhalative
|
US9345664B2
(en)
|
2003-09-02 |
2016-05-24 |
Norton Healthcare Ltd |
Process for preparing a medicament
|
PE20050489A1
(en)
|
2003-11-04 |
2005-09-02 |
Glaxo Group Ltd |
ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS
|
WO2005102429A1
(en)
|
2004-04-21 |
2005-11-03 |
Innovata Biomed Limited |
Inhaler
|
GB0409197D0
(en)
|
2004-04-24 |
2004-05-26 |
Innovata Biomed Ltd |
Device
|
PE20060259A1
(en)
|
2004-04-27 |
2006-03-25 |
Glaxo Group Ltd |
QUINUCLIDINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR
|
US7723306B2
(en)
*
|
2004-05-10 |
2010-05-25 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
|
US7611709B2
(en)
*
|
2004-05-10 |
2009-11-03 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
|
US7727962B2
(en)
*
|
2004-05-10 |
2010-06-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powder comprising new compositions of oligosaccharides and methods for their preparation
|
DE102004048389A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Modification of surfaces of lactose as adjuvant for use with powder inhalants
|
DE102004048390A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
New powder inhalants based on modified lactose mixtures as adjuvant
|
CN104177448A
(en)
|
2005-02-10 |
2014-12-03 |
葛兰素集团有限公司 |
Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom
|
WO2010010538A2
(en)
|
2008-07-24 |
2010-01-28 |
L'air Liquide-Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude |
Heteroleptic cyclopentadienyl transition metal precursors for deposition of transition metal-containing films
|
US9925282B2
(en)
|
2009-01-29 |
2018-03-27 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
ES2739352T3
(en)
|
2009-02-26 |
2020-01-30 |
Glaxo Group Ltd |
Pharmaceutical formulations comprising 4 - {(1R) -2 - [(6- {2 - [(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
PT106094A
(en)
|
2012-01-13 |
2013-07-15 |
Hovione Farmaciencia S A |
ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
|
US20150165038A1
(en)
*
|
2012-02-10 |
2015-06-18 |
Arven llac Sanayi Ve Ticaret A.S. |
Compositions comprising muscarinic receptor antagonist and sorbitol
|
WO2014007769A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Compositions comprising muscarinic receptor antagonist and glucose anhydrous
|
WO2014007772A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising glucose anhydrous
|
WO2014007771A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising muscarinic receptor antagonist
|
WO2014066318A1
(en)
|
2012-10-25 |
2014-05-01 |
The General Hospital Corporation |
Combination therapies for the treatment of alzheimer's disease and related disorders
|
GB201305825D0
(en)
|
2013-03-28 |
2013-05-15 |
Vectura Ltd |
New use
|
US10525005B2
(en)
|
2013-05-23 |
2020-01-07 |
The General Hospital Corporation |
Cromolyn compositions and methods thereof
|
US10307370B2
(en)
|
2013-10-08 |
2019-06-04 |
AI Therapeutics, Inc. |
Rapamycin for the treatment of lymphangioleiomyomatosis
|
CA2928028A1
(en)
|
2013-10-22 |
2015-04-30 |
The General Hospital Corporation |
Cromolyn derivatives and related methods of imaging and treatment
|
HUE062742T2
(en)
|
2014-04-04 |
2023-12-28 |
Ai Therapeutics Inc |
An inhalable rapamycin formulation for treating age-related conditions
|
MX2017004440A
(en)
|
2014-10-07 |
2017-11-01 |
Lam Therapeutics Inc |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension.
|
JP2019524865A
(en)
|
2016-08-31 |
2019-09-05 |
ザ ジェネラル ホスピタル コーポレイション |
Macrophages / microglia in neuroinflammation associated with neurodegenerative diseases
|
UA126238C2
(en)
*
|
2017-06-28 |
2022-09-07 |
Філіп Морріс Продактс С.А. |
Container with particles for use with inhaler
|
CA3070386A1
(en)
|
2017-07-20 |
2019-01-24 |
Aztherapies, Inc. |
Powdered formulations of cromolyn sodium and ibuprofen
|
AU2019299347A1
(en)
|
2018-07-02 |
2021-01-21 |
Aztherapies, Inc. |
Powdered formulations of cromolyn sodium and alpha-lactose
|
WO2020031119A1
(en)
|
2018-08-07 |
2020-02-13 |
Norton (Waterford) Limited |
Application of raman spectroscopy for the manufacture of inhalation powders
|
WO2022043481A1
(en)
|
2020-08-28 |
2022-03-03 |
Universität Linz |
Use of leoligin in the prevention of tissue damage
|